1. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1334,
2002,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
2. |
Matrix metalloproteinase inhibitors - much work to be done |
|
Inpharma Weekly,
Volume &NA;,
Issue 1334,
2002,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
3. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1334,
2002,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
4. |
Hylan-G-F-20 for OA of the knee cost saving in US managed care |
|
Inpharma Weekly,
Volume &NA;,
Issue 1334,
2002,
Page 5-6
Bruce Sylvester,
Preview
|
|
摘要:
Hylan-G-F-20 ['Synvisc'] is an effective therapy for many patients with osteoarthritis (OA) of the knee; it delays total knee replacement procedures, which generates cost savings in the managed-care setting, researchers reported at the Annual Meeting of the American Academy of Orthopaedic Surgeons [Dallas, US; February 2002]. In their study, the researchers developed a model to study the economic impact of introducing viscosupplementation for the treatment of OA of the knee in a managed-care setting. Hylan-G-F-20 is an injectable agent that restores the viscoelastic properties of synovial fluids, reduces pain, improves mobility, and restores homeostasis to the joint. The treatment regimen typically involves 3 intra-articular injections, and can be effective at all stages of OA.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
5. |
Fluticasone propionate favoured for asthma control |
|
Inpharma Weekly,
Volume &NA;,
Issue 1334,
2002,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
6. |
News in brief... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1334,
2002,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
7. |
News in brief... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1334,
2002,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
8. |
Tecastemizole: rapid and sustained activity in allergic rhinitis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1334,
2002,
Page 9-10
Raewyn Poole,
Preview
|
|
摘要:
Tecastemizole ['Soltara'], a novel antihistamine, has rapid and prolonged activity in the treatment of seasonal allergic rhinitis, according to results from three phase III studies presented at the 58th Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) [New York, US; March 2002]. In one study, single doses of tecastemizole 30mg provided rapid and sustained relief of symptoms, starting as early as 20 minutes after administration. Two separate studies showed that once-daily administration of tecastemizole for two weeks was effective in reducing total, nasal and non-nasal symptoms from the first day of treatment. Tecastemizole was well tolerated in all three studies, with the incidences of adverse events being comparable to the placebo groups, and no evidence of QTc interval prolongation.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
9. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1334,
2002,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
10. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1334,
2002,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|